P. Savi

I. Castan-Laurell, C. Dray, O. Kunduzova, 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Identification and Biological Activity of the Active Metabolite of Clopidogrel

J. Herbert, J. Maffrand, M. Pascal, 2000, Thrombosis and Haemostasis.

Hypercholesterolemia does not affect the antiplatelet activity of clopidogrel.

J. Herbert, P. Savi, A. Bernat, 1995, Platelets.

The Antiaggregating Activity of Clopidogrel Is due to a Metabolic Activation by the Hepatic Cytochrome P450-1A

J. Herbert, J. Maffrand, P. Savi, 1994, Thrombosis and Haemostasis.

P2Y receptors: in the middle of the road.

J. Herbert, J. Boeynaems, D. Communi, 2000, Trends in pharmacological sciences.

Influence of Heparin Mimetics on Assembly of the FGF·FGFR4 Signaling Complex

K. Saxena, H. Schwalbe, M. Mohammadi, 2010, The Journal of Biological Chemistry.

An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma

N. Brémond, P. Savi, Sébastien Roy, 2011, Thrombosis and Haemostasis.

Clopidogrel inhibits platelet-leukocyte adhesion and plateletdependent leukocyte activation

P. Savi, V. Evangelista, S. Manarini, 2005, Thrombosis and Haemostasis.

P2y(12), a new platelet ADP receptor, target of clopidogrel.

J. Herbert, N. Delesque, P. Savi, 2001, Biochemical and biophysical research communications.

The antiaggregating activity of clopidogrel is not affected by N-acetyl L-cysteine

J. Herbert, P. Savi, A. Lalé, 2003, Thrombosis and Haemostasis.

IL-4 inhibits LPS-, IL-1 beta- and TNF alpha-induced expression of tissue factor in endothelial cells and monocytes.

J. Herbert, P. Savi, M. Laplace, 1992, FEBS letters.

P2Y12, A New Platelet ADP Receptor, Target of Clopidogrel

J. Herbert, P. Savi, 2003, Seminars in vascular medicine.

Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel.

J. Herbert, J. Maffrand, P. Savi, 1992, Biochemical pharmacology.

The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts.

Pascual Ferrara, Françoise Bono, P. Ferrara, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation.

M. Humbert, P. Nurden, J. Herbert, 1996, Arteriosclerosis, thrombosis, and vascular biology.

Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.

J. Herbert, P. Savi, 2005, Seminars in thrombosis and hemostasis.

Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy.

P. Carmeliet, S. Goff, D. Collen, 2005, The Journal of clinical investigation.

Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration.

G. Neufeld, J. Herbert, F. Bono, 2006, Blood.

A novel inhibitor of p75-neurotrophin receptor improves functional outcomes in two models of traumatic brain injury

Adam R Ferguson, G. Manley, M. Beattie, 2016, Brain : a journal of neurology.

P2Y receptor antagonists in thrombosis.

J. Herbert, J. Boeynaems, P. Savi, 2005, Current opinion in investigational drugs.

P2Y4 nucleotide receptor: a novel actor in post-natal cardiac development

J. Balligand, C. Dessy, C. Gachet, 2012, Angiogenesis.

Binding of [3H]-2-methylthio ADP to rat platelets--effect of clopidogrel and ticlopidine.

J. Herbert, J. Maffrand, P. Savi, 1994, The Journal of pharmacology and experimental therapeutics.

Malformin-A1 inhibits the binding of interleukin-1 beta (IL1 beta) and suppresses the expression of tissue factor in human endothelial cells and monocytes.

J. Herbert, P. Savi, M. Laplace, 1994, Biochemical pharmacology.

P2Y receptors: New subtypes, new functions

J. Boeynaems, D. Communi, P. Savi, 2003 .

ADP receptors on platelets and ADP‐selective antiaggregating agents

J. Herbert, P. Savi, 1996 .

Experimental and clinical pharmacology of pentosan polysulfate.

J. Herbert, J. Maffrand, P. Savi, 1991, Seminars in thrombosis and hemostasis.

FcgammaRIIA requires a Gi-dependent pathway for an efficient stimulation of phosphoinositide 3-kinase, calcium mobilization, and platelet aggregation.

J. Herbert, B. Payrastre, M. Plantavid, 2000, Blood.

Studies on the Binding of 3H-SR121566, an Inhibitor of Gp IIb-IIIa Activation

J. Herbert, P. Savi, G. Zamboni, 2001, Thrombosis and Haemostasis.

Effect of clopidogrel treatment on ADP‐induced phosphorylations in rat platelets

J. Herbert, J. Maclouf, P. Savi, 1997, British journal of haematology.

ADP Receptors on Platelets and ADP-Selective Antiaggregating Agents

J. Herbert, P. Savi, 1996 .

TNF-alpha induced PMN apoptosis in whole human blood: protective effect of SSR180575, a potent and selective peripheral benzodiazepine ligand.

F. Bono, P. Savi, V. Vin, 2010, Biochemical and biophysical research communications.

Influence of Heparin Mimetics on Assembly of the FGF·FGFR4 Signaling Complex

K. Saxena, H. Schwalbe, M. Mohammadi, 2010, The Journal of Biological Chemistry.

Influence of endothelial cell protein C receptor on plasma clearance of factor VIIa

N. Brémond, P. Savi, Sébastien Roy, 2012 .